Miguel A. Piris

List of Publications by Year
in descending order

421 papers	29,218 citations	5876 81 h-index	7333 152 g-index
431 all docs	431 docs citations	431 times ranked	29177 citing authors

#	Article	IF	Citations
1	International network of cancer genome projects. Nature, 2010, 464, 993-998.	13.7	2,114
2	Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics, 2005, 37, 391-400.	9.4	1,710
3	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 2011, 475, 101-105.	13.7	1,364
4	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4021-4031.	0.6	596
5	A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. Clinical Cancer Research, 2009, 15, 5494-5502.	3.2	577
6	Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology, 2002, 41, 1-29.	1.6	576
7	Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the â€˜cutaneous variantâ€™1. British Journal of Haematology, 2004, 127, 173-183.	1.2	535
8	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nature Genetics, 2014, 46, 166-170.	9.4	534
9	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	0.6	512
10	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Research, 2010, 70, 1408-1418.	0.4	429
11	Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells. Clinical Cancer Research, 2005, 11, 1467-1473.	3.2	401
12	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Cancer Cell, 2015, 27, 516-532.	7.7	378
13	Cell cycle deregulation in B-cell lymphomas. Blood, 2003, 101, 1220-1235.	0.6	329
14	Mantle cell lymphoma. , 1998, 82, 567-575.		302
15	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 3986-3996.	0.6	301
16	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 2012, 26, 2103-2113.	3.3	301
17	The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell, 2006, 9, 301-312.	7.7	299
18	A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis. Cancer Research, 2007, 67, 3450-3460.	0.4	274

#	Article	IF	Citations
19	Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia, 2008, 22, 487-495.	3.3	244
20	Progression in Cutaneous Malignant Melanoma Is Associated with Distinct Expression Profiles. American Journal of Pathology, 2004, 164, 193-203.	1.9	226
21	Primary Cutaneous CD4+ Small/Medium-sized Pleomorphic T-cell Lymphoma Expresses Follicular T-cell Markers. American Journal of Surgical Pathology, 2009, 33, 81-90.	2.1	226
22	Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood, 2003, 101, 681-689.	0.6	224
23	The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Research, 2009, 19, 438-451.	2.4	218
24	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood, 2013, 122, 2673-2682.	0.6	208
25	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2013, 121, 2715-2724.	0.6	206
26	Targeting the T cell receptor Î²-chain constant region for immunotherapy of T cell malignancies. Nature Medicine, 2017, 23, 1416-1423.	15.2	196
27	PLCG1 mutations in cutaneous T-cell lymphomas. Blood, 2014, 123, 2034-2043.	0.6	193
28	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 2002, 100, 1648-1654.	0.6	184
29	Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood, 2005, 105, 4445-4454.	0.6	180
30	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood, 2010, 116, 1479-1488.	0.6	174
31	p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. British Journal of Cancer, 1994, 69, 337-341.	2.9	173
32	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood, 2008, 112, 3088-3098.	0.6	173
33	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 2011, 117, 1595-1604.	0.6	173
34	EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Modern Pathology, 2012, 25, 968-982.	2.9	172
35	Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells. Cancer Cell, 2009, 16, 103-114.	7.7	163
36	Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood, 2002, 99, 1299-1304.	0.6	158

#	Article	IF	Citations
37	7q31-32 Allelic Loss Is a Frequent Finding in Splenic Marginal Zone Lymphoma. American Journal of Pathology, 1999, 154, 1583-1589.	1.9	154
38	Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood, 2003, 102, 1042-1050.	0.6	153
39	Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia, 2014, 28, 823-829.	3.3	148
40	Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica, 2007, 92, 1059-1066.	1.7	142
41	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica, 2013, 98, 255-263.	1.7	142
42	Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood, 2005, 106, 1831-1838.	0.6	138
43	FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia, 2005, 19, 2247-2253.	3.3	131
44	Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood, 2006, 108, 662-668.	0.6	131
45	The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research, 2003, 63, 8226-32.	0.4	130
46	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica, 2010, 95, 1342-1349.	1.7	128
47	Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis. Cancer Research, 2006, 66, 5744-5756.	0.4	127
48	Progression to Large B-Cell Lymphoma in Splenic Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2001, 25, 1268-1276.	2.1	126
49	Expression of the NF-Î°B targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. Journal of Pathology, 2005, 206, 123-134.	2.1	126
50	Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO Journal, 2009, 28, 8-20.	3.5	125
51	PD-1, a Follicular T-cell Marker Useful for Recognizing Nodular Lymphocyte-predominant Hodgkin Lymphoma. American Journal of Surgical Pathology, 2008, 32, 1252-1257.	2.1	122
52	TCR-Î³ Expression in Primary Cutaneous T-cell Lymphomas. American Journal of Surgical Pathology, 2013, 37, 375-384.	2.1	122
53	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood, 2003, 101, 4042-4046.	0.6	121
54	Inactivation of the Lamin A/C Gene by CpG Island Promoter Hypermethylation in Hematologic Malignancies, and Its Association With Poor Survival in Nodal Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2005, 23, 3940-3947.	0.8	119

#	Article	IF	Citations
55	Prevalence and Clinical Implications of Epsteinâ€“Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries. Clinical Cancer Research, 2014, 20, 2338-2349.	3.2	117
56	Hydroa-Like Cutaneous T-Cell Lymphoma: A Clinicopathologic and Molecular Genetic Study of 16 Pediatric Cases from Peru. Applied Immunohistochemistry and Molecular Morphology, 2002, 10, 7-14.	0.6	116
57	Peripheral T-cell Lymphoma With Follicular T-cell Markers. American Journal of Surgical Pathology, 2008, 32, 1787-1799.	2.1	115
58	Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia, 2014, 28, 1334-1340.	3.3	115
59	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2014, 27, 958-971.	2.9	112
60	Loss of p16/INK4A Protein Expression in Non-Hodgkin's Lymphomas Is a Frequent Finding Associated with Tumor Progression. American Journal of Pathology, 1998, 153, 887-897.	1.9	111
61	Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia, 2012, 26, 1638-1646.	3.3	108
62	Identification of Genes Involved in Resistance to Interferon-Î± in Cutaneous T-Cell Lymphoma. American Journal of Pathology, 2002, 161, 1825-1837.	1.9	106
63	Nodal Marginal Zone Lymphoma: A Heterogeneous Tumor. American Journal of Surgical Pathology, 2003, 27, 762-771.	2.1	106
64	EBV-associated Cutaneous NK/T-cell Lymphoma. American Journal of Surgical Pathology, 2010, 34, 1773-1782.	2.1	106
65	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunology Research, 2019, 7, 644-657.	1.6	106
66	Anomalous High p27/KIP1 Expression in a Subset of Aggressive B-Cell Lymphomas Is Associated With Cyclin D3 Overexpression. p27/KIP1â€”Cyclin D3 Colocalization in Tumor Cells. Blood, 1999, 94, 765-772.	0.6	105
67	miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle, 2010, 9, 3297-3305.	1.3	102
68	Large B-cell lymphoma with Hodgkin's features. Histopathology, 2005, 47, 101-110.	1.6	101
69	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 764-769.	3.3	100
70	The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica, 2010, 95, 432-439.	1.7	99
71	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood, 2013, 122, 2683-2693.	0.6	98
72	P53 protein expression in lymphomas and reactive lymphoid tissue. Journal of Pathology, 1992, 166, 235-241.	2.1	97

#	Article	IF	Citations
73	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood, 2016, 127, 221-232.	0.6	97
74	Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia, 2006, 20, 1047-1054.	3.3	95
75	p16INK4a Gene Alterations Are Frequent in Lesions of Mycosis Fungoides. American Journal of Pathology, 2000, 156, 1565-1572.	1.9	94
76	Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica, 2010, 95, 613-621.	1.7	93
77	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget, 2016, 7, 2401-2416.	0.8	93
78	Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. Blood, 2012, 119, e9-e21.	0.6	91
79	Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nature Reviews Cancer, 2006, 6, 437-448.	12.8	90
80	miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood, 2011, 118, 1034-1040.	0.6	90
81	Novel Genomic Imbalances in B-Cell Splenic Marginal Zone Lymphomas Revealed by Comparative Genomic Hybridization and Cytogenetics. American Journal of Pathology, 2001, 158, 1843-1850.	1.9	88
82	Building an Outcome Predictor Model for Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2004, 164, 613-622.	1.9	87
83	Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia, 2009, 23, 1847-1857.	3.3	87
84	Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Modern Pathology, 2006, 19, 684-694.	2.9	83
85	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood, 2011, 118, 5517-5527.	0.6	83
86	Cutaneous Follicular B-Cell Lymphoma. American Journal of Surgical Pathology, 2001, 25, 875-883.	2.1	82
87	Risk stratification for <scp>S</scp>plenic <scp>M</scp>arginal <scp>Z</scp>one <scp>L</scp>ymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. British Journal of Haematology, 2012, 159, 164-171.	1.2	81
88	Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica, 2010, 95, 1122-1129.	1.7	79
89	MicroRNA signatures in B-cell lymphomas. Blood Cancer Journal, 2012, 2, e57-e57.	2.8	79
90	Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers. Modern Pathology, 2009, 22, 1006-1015.	2.9	78

#	Article	IF	Citations
91	Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. Journal of Investigative Dermatology, 2017, 137, 197-206.	0.3	78
92	Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology, 2006, 48, 481-504.	1.6	77
93	Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Haematologica, 2008, 93, 670-679.	1.7	77
94	The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica, 2006, 91, 1605-12.	1.7	77
95	Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia, 2003, 17, 2016-2024.	3.3	76
96	MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma. American Journal of Surgical Pathology, 2015, 39, 644-651.	2.1	76
97	Mantle cell lymphoma: transcriptional regulation by microRNAs. Leukemia, 2010, 24, 1335-1342.	3.3	72
98	Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget, 2015, 6, 5615-5633.	0.8	72
99	Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma?. Histopathology, 2002, 40, 22-30.	1.6	70
100	Genome wide DNAâ€profiling of HIVâ€related Bâ€cell lymphomas. British Journal of Haematology, 2010, 148, 245-255.	1.2	70
101	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica, 2006, 91, 467-74.	1.7	70
102	Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood, 2008, 111, 351-358.	0.6	69
103	Overall Survival in Aggressive B-Cell Lymphomas Is Dependent on the Accumulation of Alterations in p53, p16, and p27. American Journal of Pathology, 2001, 159, 205-213.	1.9	68
104	The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood, 2012, 120, 1782-1790.	0.6	68
105	A marginal zone pattern may be found in different varieties of nonâ€Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by Bâ€cell lymphomas simulating splenic marginal zone lymphoma. Histopathology, 1998, 33, 230-239.	1.6	67
106	Intrafollicular neoplasia/in situ follicular lymphoma: review of a series of 13 cases. Histopathology, 2010, 56, 658-662.	1.6	66
107	Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. Modern Pathology, 2009, 22, 753-761.	2.9	65
108	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia, 2018, 20, 574-593.	2.3	64

#	Article	IF	Citations
109	Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFÎºB transcription factors. Journal of Pathology, 2004, 204, 528-537.	2.1	63
110	Lymphoma microenvironment: culprit or innocent?. Leukemia, 2008, 22, 49-58.	3.3	63
111	Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Modern Pathology, 2017, 30, 85-94.	2.9	63
112	Analysis of Octamer-Binding Transcription Factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in Lymphomas. Modern Pathology, 2002, 15, 211-220.	2.9	62
113	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 5597-5614.	0.8	61
114	Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkinâ€™s Lymphoma Study Group. Journal of Clinical Oncology, 2004, 22, 1664-1673.	0.8	60
115	Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood, 2004, 103, 2351-2357.	0.6	60
116	Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. Blood, 2011, 117, 6255-6266.	0.6	60
117	Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma. Leukemia, 2014, 28, 1103-1112.	3.3	60
118	Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2014, 20, 5113-5123.	3.2	60
119	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood, 2016, 128, 3083-3100.	0.6	59
120	Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica, 2015, 100, e450-e453.	1.7	59
121	Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. Pathology, 2020, 52, 154-165.	0.3	58
122	miR-217 is an oncogene that enhances the germinal center reaction. Blood, 2014, 124, 229-239.	0.6	57
123	Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone Bâ€cell lymphoma. British Journal of Haematology, 1997, 98, 446-449.	1.2	56
124	T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. Histopathology, 2002, 41, 216-229.	1.6	56
125	Polycomb proteins in hematologic malignancies. Blood, 2010, 116, 5465-5475.	0.6	56
126	Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica, 2012, 97, 1080-1084.	1.7	56

#	Article	IF	Citations
127	Aberrant Bcl6 Protein Expression in Mantle Cell Lymphoma. American Journal of Surgical Pathology, 2004, 28, 1051-1056.	2.1	55
128	The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma. Infectious Agents and Cancer, 2014, 9, 12.	1.2	55
129	Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia, 2016, 30, 361-372.	3.3	55
130	Nodal and splenic marginal zone B cell lymphomas. Hematological Oncology, 2005, 23, 108-118.	0.8	54
131	p14ARF nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood, 2002, 99, 1411-1418.	0.6	53
132	Single nucleotide polymorphismâ€arrays provide new insights in the pathogenesis of postâ€transplant diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2010, 149, 569-577.	1.2	53
133	Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. Leukemia and Lymphoma, 2012, 53, 185-194.	0.6	53
134	The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. Blood, 2014, 123, 2893-2894.	0.6	53
135	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood, 2015, 125, 1922-1931.	0.6	53
136	Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia, 2007, 21, 1984-1991.	3.3	52
137	NIK Controls Classical and Alternative NF-Îºb Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells. Clinical Cancer Research, 2013, 19, 2319-2330.	3.2	52
138	B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica, 2014, 99, 222-231.	1.7	52
139	Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. Blood, 2017, 129, 1042-1045.	0.6	52
140	Retinoblastoma (rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction. Journal of Pathology, 1993, 169, 405-412.	2.1	51
141	Crystal-storing histiocytosis and immunocytoma associated with multifocal fibrosclerosis. Histopathology, 1998, 33, 459-464.	1.6	51
142	Lymph Node Involvement by Splenic Marginal Zone Lymphoma: Morphological and Immunohistochemical Features. American Journal of Surgical Pathology, 1997, 21, 772-780.	2.1	51
143	Splenic marginal zone lymphoma with increased number of blasts: An aggressive variant?. Human Pathology, 1999, 30, 1153-1160.	1.1	50
144	Large B-cell Lymphoma Presenting in the Spleen. American Journal of Surgical Pathology, 2003, 27, 895-902.	2.1	50

#	Article	IF	Citations
145	Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naÃ¯ve patients. Molecular Cancer Therapeutics, 2005, 4, 814-823.	1.9	50
146	MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia, 2007, 21, 2547-2549.	3.3	50
147	A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12461-12466.	3.3	50
148	Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma. Leukemia, 2012, 26, 180-183.	3.3	50
149	Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features. Histopathology, 2015, 66, 846-855.	1.6	50
150	Composite Hodgkin Lymphoma and Mantle Cell Lymphoma. American Journal of Surgical Pathology, 2003, 27, 1577-1580.	2.1	49
151	Longâ€term followâ€up of doseâ€adjusted EPOCH plus rituximab (DAâ€EPOCHâ€R) in untreated patients with poor prognosis large Bâ€cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. British Journal of Haematology, 2015, 169, 188-198.	1.2	49
152	Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 2022, 139, 732-747.	0.6	49
153	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2015, 28, 1555-1573.	2.9	48
154	Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2016, 22, 3593-3605.	3.2	48
155	A Short Mutational Hot Spot in the First Intron of BCL-6 Is Associated with Increased BCL-6 Expression and with Longer Overall Survival in Large B-Cell Lymphomas. American Journal of Pathology, 2002, 160, 1371-1380.	1.9	47
156	p16INK4a Is Selectively Silenced in the Tumoral Progression of Mycosis Fungoides. Laboratory Investigation, 2002, 82, 123-132.	1.7	47
157	A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood, 2010, 116, e12-e17.	0.6	47
158	Genomic lesions associated with a different clinical outcome in diffuse large Bâ€Cell lymphoma treated with Râ€CHOPâ€21. British Journal of Haematology, 2010, 151, 221-231.	1.2	47
159	SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. Blood, 2013, 121, 643-647.	0.6	47
160	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia, 2017, 31, 625-636.	3.3	47
161	TCL1A expression delineates biological and clinical variability in B-cell lymphoma. Modern Pathology, 2009, 22, 206-215.	2.9	46
162	Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large Bâ€cell lymphomas. Hematological Oncology, 2010, 28, 62-67.	0.8	46

#	Article	IF	Citations
163	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 2630-2640.	0.6	46
164	Highâ€tthroughput sequencing analysis of the chromosome 7q32 deletion reveals <scp>IRF</scp>5 as a potential tumour suppressor in splenic marginalâ€zone lymphoma. British Journal of Haematology, 2012, 158, 712-726.	1.2	45
165	Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. Modern Pathology, 2013, 26, 889-901.	2.9	45
166	Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. Blood, 2013, 122, 2233-2241.	0.6	45
167	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 2002, 100, 1648-54.	0.6	45
168	Detection of thebcl-1 Rearrangement at the Major Translocation Cluster in Frozen and Paraffin-Embedded Tissues of Mantle Cell Lymphomas by Polymerase Chain Reaction. American Journal of Clinical Pathology, 1996, 105, 532-537.	0.4	44
169	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2002, 10, 7-14.	2.0	44
170	Primary Cutaneous Large B-Cell Lymphoma. American Journal of Surgical Pathology, 2001, 25, 307-315.	2.1	43
171	True Histiocytic Lymphoma of the Stomach Associated with Low-grade B-cell Mucosa-associated Lymphoid Tissue (Malt)-type Lymphoma. American Journal of Surgical Pathology, 1996, 20, 1406-1411.	2.1	43
172	Persistent and Generalized Lymphadenopathy: A Lesion of Follicular Dendritic Cells?: An Immunohistologic and Ultrastructural Study. American Journal of Clinical Pathology, 1987, 87, 716-724.	0.4	42
173	Frequency ofBCL2andBCL6translocations in follicular lymphoma: Relation with histological and clinical features. Leukemia and Lymphoma, 2008, 49, 95-101.	0.6	42
174	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia, 2015, 29, 1390-1401.	3.3	42
175	Splenic Follicular Lymphoma. American Journal of Surgical Pathology, 2009, 33, 730-738.	2.1	41
176	Deregulated Expression of the Polycomb-Group Protein SUZ12 Target Genes Characterizes Mantle Cell Lymphoma. American Journal of Pathology, 2010, 177, 930-942.	1.9	41
177	Single nucleotide variation in the TP53 3â€² untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4529-4540.	0.6	41
178	The Spectrum of EBV-Positive Mucocutaneous Ulcer. American Journal of Surgical Pathology, 2019, 43, 201-210.	2.1	41
179	p27KIP1 is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome. British Journal of Cancer, 1999, 80, 1427-1434.	2.9	40
180	The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma. Leukemia, 2008, 22, 1268-1272.	3.3	40

#	Article	IF	Citations
181	Lightâ€chainâ€restricted germinal centres in reactive lymphadenitis: report of eight cases. Histopathology, 2008, 52, 436-444.	1.6	40
182	Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. Blood, 2012, 120, 812-821.	0.6	40
183	Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leukemia and Lymphoma, 2014, 55, 929-931.	0.6	40
184	Epstein-Barr Virus-Latent Membrane Protein 1 Expression Has a Favorable Influence in the Outcome of Patients with Hodgkin's Disease Treated with Chemotherapy. Leukemia and Lymphoma, 2000, 39, 563-572.	0.6	39
185	Extreme sensitivity to YondelisÂ® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. Journal of Cellular Biochemistry, 2007, 100, 339-348.	1.2	39
186	E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma. Cancer Research, 2009, 69, 4052-4058.	0.4	39
187	Micro<scp>RNA</scp> signatures and treatment response in patients with advanced classical Hodgkin lymphoma. British Journal of Haematology, 2013, 162, 336-347.	1.2	39
188	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2017, 187, 1700-1716.	1.9	39
189	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Modern Pathology, 2019, 32, 741-754.	2.9	39
190			

#	Article	IF	Citations
199	Variability in the Degree of Expression of Phosphorylated IÎºBÎ± in Chronic Lymphocytic Leukemia Cases With Nodal Involvement. Clinical Cancer Research, 2004, 10, 6796-6806.	3.2	35
200	Overexpression of human DNA polymerase Â (Pol Â) in a Burkitt's lymphoma cell line affects the somatic hypermutation rate. Nucleic Acids Research, 2004, 32, 5861-5873.	6.5	35
201	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 23157-23180.	0.8	35
202	Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clinical and Experimental Metastasis, 1989, 7, 213-226.	1.7	34
203	Gastric B-cell mucosa associated lymphoid tissue lymphoma: a clinicopathological study in 56 patients.. Gut, 1992, 33, 1307-1311.	6.1	34
204	Mouse cDNA microarray analysis uncovers Slug targets in mouse embryonic fibroblasts. Genomics, 2006, 87, 113-118.	1.3	34
205	Proliferation centers in chronic lymphocytic leukemia: the niche where NF-ÎºB activation takes place. Leukemia, 2010, 24, 872-876.	3.3	34
206	MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. Journal of Pathology, 1995, 177, 27-34.	2.1	33
207	Other Cancers in Patients with Gastric Malt Lymphoma. Leukemia and Lymphoma, 1999, 33, 161-168.	0.6	33
208	Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica, 2013, 98, 57-64.	1.7	33
209	Splenic marginal zone lymphoma. Best Practice and Research in Clinical Haematology, 2017, 30, 56-64.	0.7	33
210	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. Oncotarget, 2017, 8, 111386-111395.	0.8	33
211	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget, 2015, 6, 13933-13945.	0.8	33
212	The detection of B-cell monoclonal populations by polymerase chain reaction: Accuracy of approach and application in gastric endoscopic biopsy specimens. Human Pathology, 1993, 24, 1184-1188.	1.1	32
213	Prevalence and clinical implications of cyclin D1 expression in diffuse large Bâ€cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL RituximabâCHOP Consortium Program. Cancer, 2014, 120, 1818-1829.	2.0	32
214	Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large Bâ€cell lymphomas. Cancer, 2009, 115, 3728-3737.	2.0	31
215	Clinical and diagnostic relevance of NOTCH2 -and KLF2 -mutations in splenic marginal zone lymphoma. Haematologica, 2017, 102, e310-e312.	1.7	31
216	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. PLoS ONE, 2019, 14, e0212813.	1.1	31

#	Article	IF	Citations
217	Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer Journal, 2020, 10, 49.	2.8	31
218	Epstein-Barr virus-positive systemic NK/T-cell lymphomas in children: report of six cases. Histopathology, 2011, 59, 1183-1193.	1.6	30
219	Incidental and Isolated Follicular Lymphoma In Situ and Mantle Cell Lymphoma In Situ Lack Clinical Significance. American Journal of Surgical Pathology, 2016, 40, 943-949.	2.1	30
220	Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. Oncotarget, 2018, 9, 16124-16133.	0.8	30
221	CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma. PLoS ONE, 2015, 10, e0125203.	1.1	30
222	Cutaneous Presentation of Follicular Lymphomas. Modern Pathology, 2001, 14, 913-919.	2.9	29
223	Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. Histopathology, 2005, 46, 241-255.	1.6	29
224	Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. Modern Pathology, 2006, 19, 1055-1067.	2.9	29
225	Diffuse large Bâ€cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. Hematological Oncology, 2011, 29, 38-41.	0.8	29
226	RelA NF-ÎºB subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging, 2016, 8, 3321-3340.	1.4	29
227	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. Haematologica, 2010, 95, 2056-2062.	1.7	28
228	DUSP22-rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers. Haematologica, 2019, 104, e158-e162.	1.7	28
229	Unique Phenotypic Profile of Monocytoid B Cells. American Journal of Pathology, 2001, 158, 1363-1369.	1.9	27
230	Expression pattern of XBP1(S) in human B-cell lymphomas. Haematologica, 2009, 94, 419-422.	1.7	27
231	Down-regulation of specific miRNAs enhances the expression of the gene Smoothened and contributes to T-cell lymphoblastic lymphoma development. Carcinogenesis, 2013, 34, 902-908.	1.3	27
232	NFÎºB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Modern Pathology, 2014, 27, 1331-1337.	2.9	27
233	NF-ÎºB directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas. Nucleic Acids Research, 2014, 42, 11025-11039.	6.5	27
234	Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. Leukemia, 2016, 30, 94-103.	3.3	27

#	Article	IF	Citations
235	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. Journal of Hematology and Oncology, 2020, 13, 148.	6.9	27
236	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget, 2016, 7, 18036-18049.	0.8	26
237	Advancedâ€stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factorâ€ÎºB and nuclear factor of activated T cells pathways. British Journal of Dermatology, 2020, 182, 147-155.	1.4	26
238	Splenic Marginal Zone Lymphoma. Advances in Anatomic Pathology, 1997, 4, 191-201.	2.4	25
239	C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas. Haematologica, 2016, 101, e336-e338.	1.7	25
240	Diseaseâ€biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations. Journal of Pathology, 2019, 247, 416-421.	2.1	25
241	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. Scientific Reports, 2021, 11, 1886.	1.6	25
242	KSHV- and EBV-associated germinotropic lymphoproliferative disorder: A rare lymphoproliferative disease of HIV patient with plasmablastic morphology, indolent course and favourable response to therapy. Leukemia and Lymphoma, 2007, 48, 1444-1447.	0.6	24
243	Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. Journal of Clinical Pathology, 2013, 66, 956-961.	1.0	24
244	Richter transformation driven by Epsteinâ€“Barr virus reactivation during therapyâ€related immunosuppression in chronic lymphocytic leukaemia. Journal of Pathology, 2018, 245, 61-73.	2.1	24
245	Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. Blood Advances, 2021, 5, 5588-5598.	2.5	24
246	p53 Expression in Non-Hodgkin's Lymphomas: A Marker of p53 Inactivation?. Leukemia and Lymphoma, 1995, 17, 35-42.	0.6	23
247	MDM2 AND p21WAF1/CIP1, WILD-TYPE p53-INDUCED PROTEINS, ARE REGULARLY EXPRESSED BY STERNBERG-REED CELLS IN HODGKIN'S DISEASE. , 1996, 180, 58-64.		23
248	Transcriptional Response of T Cells to IFN-Î±: Changes Induced in IFN-Î±-Sensitive and Resistant Cutaneous T Cell Lymphoma. Journal of Interferon and Cytokine Research, 2004, 24, 185-195.	0.5	23
249	Molecular Characterization of the Region 7q22.1 in Splenic Marginal Zone Lymphomas. PLoS ONE, 2011, 6, e24939.	1.1	23
250	Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. Blood Cancer Journal, 2019, 9, 34.	2.8	23
251	Mycosis Fungoides and SÃ©zary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. Cancers, 2021, 13, 1931.	1.7	23
252	Psoralen plus ultraviolet Aâ€ƒÂ±â€ƒinterferon-Î± treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-ÎºB and T-cell receptor pathways. British Journal of Dermatology, 2009, 160, 92-102.	1.4	22

#	Article	IF	Citations
253	Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study. Modern Pathology, 2014, 27, 281-293.	2.9	22
254	Mutational profile of primary breast diffuse large B-cell lymphoma. Oncotarget, 2017, 8, 102888-102897.	0.8	22
255	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
256	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Advances, 2020, 4, 3391-3404.	2.5	22
257	High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle. Oncotarget, 2014, 5, 4694-4708.	0.8	22
258	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2022, 28, 972-983.	3.2	22
259	Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. Oncogene, 2006, 25, 2565-2574.	2.6	21
260	Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation. Haematologica, 2015, 100, e200-e203.	1.7	21
261	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Modern Pathology, 2015, 28, 1297-1314.	2.9	21
262	Alteraciones moleculares en leucemia mieloide aguda y sus implicaciones clÃnicas y terapÃ©uticas. Medicina ClÃnica, 2018, 151, 362-367.	0.3	21
263	Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2020, 44, 657-664.	2.1	21
264	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. British Journal of Haematology, 2010, 151, 435-439.	1.2	20
265	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Molecular Cancer Research, 2021, 19, 249-260.	1.5	20
266	E2F4 plays a key role in Burkitt lymphoma tumorigenesis. Leukemia, 2012, 26, 2277-2285.	3.3	19
267	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. Annals of Oncology, 2012, 23, 729-735.	0.6	19
268	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. Modern Pathology, 2013, 26, 171-181.	2.9	19
269	Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas. Blood Cancer Journal, 2013, 3, e111-e111.	2.8	19
270	Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. Haematologica, 2015, 100, 1460-1468.	1.7	19

#	Article	IF	Citations
271	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging, 2016, 8, 345-365.	1.4	19
272	Transcriptomal profiling of the cellular response to DNA damage mediated by Slug (Snai2). British Journal of Cancer, 2008, 98, 480-488.	2.9	18
273	PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. PLoS ONE, 2014, 9, e112148.	1.1	18
274	Development of a Real-Time Reverse Transcription Polymerase Chain Reaction Assay for c-myc Expression That Allows the Identification of a Subset of c-myc+ Diffuse Large B-Cell Lymphoma. Laboratory Investigation, 2003, 83, 143-152.	1.7	17
275	Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways. Blood, 2008, 111, 1665-1676.	0.6	17
276	Evaluation of NF-Î¹B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Modern Pathology, 2015, 28, 1202-1213.	2.9	17
277	An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors. Clinical Cancer Research, 2016, 22, 2032-2040.	3.2	17
278	Mutations in the <scp>JAK</scp>/<scp>STAT</scp> pathway genes and activation of the pathway, a relevant finding in nodal Peripheral Tâ€cell lymphoma. British Journal of Haematology, 2018, 183, 497-501.	1.2	17
279	Breast implant-associated Epstein-Barr virus-positive large B-cell lymphomas: a report of three cases. Haematologica, 2020, 105, e412-e414.	1.7	17
280	Nucleolar p14ARF Overexpression in Reed-Sternberg Cells in Hodgkin's Lymphoma. American Journal of Pathology, 2002, 160, 569-578.	1.9	16
281	Primary mediastinal B-cell lymphoma: Treatment and therapeutic targets. Leukemia and Lymphoma, 2008, 49, 1050-1061.	0.6	15
282	Marginal zone lymphoma. Seminars in Diagnostic Pathology, 2011, 28, 135-145.	1.0	15
283	FAS system deregulation in T-cell lymphoblastic lymphoma. Cell Death and Disease, 2014, 5, e1110-e1110.	2.7	15
284	Castleman Disease and Rosai-Dorfman Disease. Seminars in Diagnostic Pathology, 2018, 35, 44-53.	1.0	15
285	In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. Haematologica, 2018, 103, e537-e540.	1.7	15
286	Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. Leukemia and Lymphoma, 2012, 53, 812-819.	0.6	14
287	Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options. Expert Review of Anticancer Therapy, 2016, 16, 411-421.	1.1	14
288	Mycosis fungoides progression could be regulated by microRNAs. PLoS ONE, 2018, 13, e0198477.	1.1	14

#	Article	IF	Citations
289	Evaluation of the International Index in the Prognosis of High Grade Gastric Malt Lymphoma. Leukemia and Lymphoma, 1996, 24, 159-163.	0.6	13
290	Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma. Haematologica, 2012, 97, 1614-1616.	1.7	13
291	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. British Journal of Cancer, 2017, 117, 1685-1688.	2.9	13
292	An A91V SNP in the Perforin Gene Is Frequently Found in NK/T-Cell Lymphomas. PLoS ONE, 2014, 9, e91521.	1.1	13
293	Integrated profiling of diffuse large Bâ€cell lymphoma with 7q gain. British Journal of Haematology, 2011, 153, 499-503.	1.2	12
294	Adult pityriasis lichenoidesâ€like mycosis fungoides: a clinical variant of mycosis fungoides. International Journal of Dermatology, 2014, 53, 1331-1338.	0.5	12
295	Somatic hypermutation signature in B-cell low-grade lymphomas. Haematologica, 2008, 93, 1186-1194.	1.7	11
296	Colorectal Adenomas Contain Multiple Somatic Mutations That Do Not Coincide with Synchronous Adenocarcinoma Specimens. PLoS ONE, 2015, 10, e0119946.	1.1	11
297	Large Cells With CD30 Expression and Hodgkin-like Features in Primary Cutaneous Marginal Zone B-Cell Lymphoma. American Journal of Surgical Pathology, 2019, 43, 1191-1202.	2.1	11
298	Kaposi's sarcoma in a patient with temporal arteritis treated with corticosteroid. Journal of the American Academy of Dermatology, 1991, 24, 1027-1028.	0.6	10
299	Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. Leukemia and Lymphoma, 2009, 50, 1699-1708.	0.6	10
300	HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphomaâ€derived cell lines. British Journal of Haematology, 2011, 152, 352-356.	1.2	10
301	Early phase of Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma of the elderly mimicking EBV-positive reactive follicular hyperplasia. Histopathology, 2011, 59, 571-575.	1.6	10
302	HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases. British Journal of Haematology, 2014, 165, 580-581.	1.2	10
303	Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis. Leukemia, 2018, 32, 1822-1826.	3.3	10
304	Spontaneously Ruptured Spleen Samples in Patients With Infectious Mononucleosis. American Journal of Clinical Pathology, 2018, 150, 310-317.	0.4	10
305	Update on peripheral T-cell lymphomas with T-helper phenotype: ÂAre there too many subtypes?. Seminars in Diagnostic Pathology, 2020, 37, 24-31.	1.0	10
306	The presence of Merkel cell carcinoma polyomavirus is associated with a distinct phenotype in neoplastic Merkel cell carcinoma cells and their tissue microenvironment. PLoS ONE, 2020, 15, e0232517.	1.1	10

#	Article	IF	Citations
307	High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations. PLoS ONE, 2020, 15, e0229743.	1.1	10
308	Ultrastructure of 26 Cases of Ki-1 Lymphomas: Morphoimmunologic Correlation. Ultrastructural Pathology, 1990, 14, 381-397.	0.4	9
309	Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells. Modern Pathology, 2011, 24, 698-707.	2.9	9
310	BCL7A protein expression in normal and malignant lymphoid tissues. British Journal of Haematology, 2013, 160, 106-109.	1.2	9
311	Primary cutaneous follicular helper Tâ€cell lymphoma. Journal of Cutaneous Pathology, 2016, 43, 164-170.	0.7	9
312	Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget, 2018, 9, 30869-30882.	0.8	9
313	Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes. Leukemia and Lymphoma, 2021, 62, 2130-2140.	0.6	9
314	Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers, 2021, 13, 2993.	1.7	9
315	IgVH and bcl6 somatic mutation analysis reveals the heterogeneity of cutaneous B-cell lymphoma, and indicates the presence of undisclosed local antigens. Modern Pathology, 2004, 17, 623-630.	2.9	8
316	Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia. Scientific Reports, 2019, 9, 975.	1.6	8
317	Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood, 2019, 134, 468-468.	0.6	8
318	Thymoma and progressive T-cell lymphocytosis. Annals of Oncology, 2007, 18, 603-604.	0.6	7
319	Follicular Tâ€cell lymphoma: description of a case with characteristic findings suggesting it is a different condition from AITL. Histopathology, 2009, 54, 902-904.	1.6	7
320	Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2009, 50, 571-581.	0.6	7
321	Angioimmunoblastic Tâ€cell lymphoma with a clonal plasma cell proliferation that underwent immunoglobulin isotype switch in the skin, coinciding with cutaneous disease progression. Journal of Cutaneous Pathology, 2016, 43, 1203-1210.	0.7	7
322	Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?. American Journal of Dermatopathology, 2019, 41, 846-850.	0.3	7
323	Epsteinâ€“Barr virusâ€associated large Bâ€cell lymphoma transformation in marginal zone Bâ€cell lymphoma: a series of four cases. Histopathology, 2020, 77, 112-122.	1.6	7
324	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer Journal, 2022, 12, 25.	2.8	7

#	Article	IF	Citations
325	Cutaneous T-Cell Lymphoma: Two Faces of the Same Coin. Journal of Investigative Dermatology, 2010, 130, 348-351.	0.3	6
326	Mutual regulation between <scp>BCL</scp>6 and a specific set of mi<scp>RNA</scp>s controls <scp>T_{FH}</scp> phenotype in peripheral Tâ€cell lymphoma. British Journal of Haematology, 2018, 182, 587-590.	1.2	6
327	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. American Journal of Clinical Pathology, 2019, 152, 277-301.	0.4	6
328	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. OncoImmunology, 2021, 10, 1928365.	2.1	6
329	Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma. Scientific Reports, 2020, 10, 6721.	1.6	5
330	Clinical and pathological characteristics of peripheral Tâ€cell lymphomas in a Spanish population: a retrospective study. British Journal of Haematology, 2021, 192, 82-99.	1.2	5
331	PLCÎ³1/PKCÎ¸ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression. Journal of Investigative Dermatology, 2022, 142, 1391-1400.e15.	0.3	5
332	Integrative Analysis of MicroRNA and Gene Expression Profiling Contributes to Understand Mantle Cell Lymphoma Pathogenesis.. Blood, 2009, 114, 2936-2936.	0.6	5
333	Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?. PLoS ONE, 2020, 15, e0241634.	1.1	5
334	Lennert's Lymphoma with Giant Multivesicular Lysosomal Bodies Optically Visible. Ultrastructural Pathology, 1992, 16, 283-290.	0.4	4
335	Childhood florid follicular hyperplasia with immunoglobulin lightâ€chain restriction in the gastrointestinal tract. Histopathology, 2014, 65, 805-813.	1.6	4
336	Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines. PLoS ONE, 2017, 12, e0177524.	1.1	4
337	EBVâ€positive nonâ€Hodgkin's lymphoma developing after phenytoin therapy. British Journal of Haematology, 1996, 95, 376-379.	1.2	3
338	Hairy cell leukemia, blastic type: description of spleen morphology and immunophenotype of a distinctive case. Leukemia and Lymphoma, 2011, 52, 1589-1592.	0.6	3
339	I. Pathological and clinical diversity in diffuse large Bâ€cell lymphoma. Hematological Oncology, 2013, 31, 23-25.	0.8	3
340	Persistent Polyclonal B-cell Lymphocytosis With Splenomegaly. American Journal of Surgical Pathology, 2013, 37, 1085-1090.	2.1	3
341	CD 30-positive transformed follicular lymphoma: two case reports and literature review. Histopathology, 2015, 67, 918-922.	1.6	3
342	Localized lymphomatoid papulosis. International Journal of Dermatology, 2015, 54, e98-100.	0.5	3

#	Article	IF	Citations
343	Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets. Leukemia and Lymphoma, 2016, 57, 134-142.	0.6	3
344	Three monocytic neoplasms in a single patient. Leukemia and Lymphoma, 2020, 61, 2523-2526.	0.6	3
345	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2011, 118, 949-949.	0.6	3
346	Activating Mutations In Fyn Kinase In Peripheral T-Cell Lymphomas. Blood, 2013, 122, 811-811.	0.6	3
347	Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. Oncotarget, 2015, 6, 25452-25465.	0.8	3
348	Posible implicaciÃ³n de las alteraciones moleculares de la vÃa de TNF en la tumorigÃ©nesis de la micosis fungoide. DescripciÃ³n de un posible chip de diagnÃ³stico molecular en micosis fungoide. Actas Dermo-sifiliogrÃ¡ficas, 2004, 95, 86-96.	0.2	2
349	Hairy cell leukemia variant. Journal of Hematopathology, 2011, 4, 13-16.	0.2	2
350	Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. Haematologica, 2014, 99, e138-e141.	1.7	2
351	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Cancer Cell, 2015, 27, 744.	7.7	2
352	pâ€‹scp›MAPK‹/scp›1 expression associated with poor prognosis in angioimmunoblastic Tâ€‹cell lymphoma patients. British Journal of Haematology, 2017, 176, 661-664.	1.2	2
353	Atypical Histiocytic Lesion Preceding a Peripheral T-Cell Lymphoma Involving the Skin Exhibiting the Same Molecular Alterations. American Journal of Dermatopathology, 2019, 41, 148-154.	0.3	2
354	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. Blood, 2018, 132, 922-922.	0.6	2
355	Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells. Blood, 2010, 116, 634-634.	0.6	2
356	Unique Versus Common: Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations. Blood, 2015, 126, 1479-1479.	0.6	2
357	Anomalous High p27/KIP1 Expression in a Subset of Aggressive B-Cell Lymphomas Is Associated With Cyclin D3 Overexpression. p27/KIP1â€”Cyclin D3 Colocalization in Tumor Cells. Blood, 1999, 94, 765-772.	0.6	2
358	Localized skinâ€‹limited blastic plasmacytoid dendritic cell neoplasm. EJHaem, 2022, 3, 560-562.	0.4	2
359	Cutaneous EBV-associated lymphoma?. Blood, 2013, 122, 3095-3095.	0.6	1
360	Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Cancer Treatment Communications, 2015, 4, S1-S11.	0.4	1

#	Article	IF	Citations
361	Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S216.	0.2	1
362	B-cell lymphoblastic lymphoma presenting as solitary temporal mass with amplification of AML1/RUNX1: case report. Hematological Oncology, 2017, 35, 380-384.	0.8	1
363	Inflammatory Cells in Atypical Eruption of Lymphocyte Recovery Carry the Same Mutations as Neoplastic Myeloid Cells. American Journal of Dermatopathology, 2020, 42, 360-363.	0.3	1
364	Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma. Annals of Hematology, 2020, 99, 391-393.	0.8	1
365	Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy. Hemato, 2021, 2, 281-304.	0.2	1
366	MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. Blood, 2019, 134, 5092-5092.	0.6	1
367	Gene Expression and Proteomic Profiling Predict Therapeutic Response to ABT-737 in Human and Mouse Models of Mantle Cell Lymphoma. Blood, 2008, 112, 608-608.	0.6	1
368	Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System. Blood, 2011, 118, 1583-1583.	0.6	1
369	NIK Is Involved In the Activation of the Classical and Alternative NF-ÎºB Pathways In Diffuse Large B Cell Lymphoma. Blood, 2010, 116, 3099-3099.	0.6	1
370	Mirna EXPRESSION SIGNATURES as PROGNOSTIC Markers IN ADVANCED Classical HODGKIN LYMPHOMA. Blood, 2010, 116, 4157-4157.	0.6	1
371	Characterization of Subclonal Changes Along Progression in Multiple Myeloma.. Blood, 2012, 120, 2924-2924.	0.6	1
372	Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms. Blood, 2021, 138, 2395-2395.	0.6	1
373	CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. Cancers, 2022, 14, 2154.	1.7	1
374	An integrated prognostic model for diffuse large Bâ€cell lymphoma treated with immunochemotherapy. EJHaem, 2022, 3, 722-733.	0.4	1
375	The use of molecular profiling for diagnosis and research in non-Hodgkin's lymphoma. Hematology Reports, 2011, 3, e2.	0.3	0
376	Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S146-S147.	0.2	0
377	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in de novo Diffuse Large B-Cell Lymphoma in Western Countries: A report from The International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S144-S145.	0.2	0
378	Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S220-S221.	0.2	0

#	Article	IF	Citations
379	Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S228.	0.2	0
380	MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S223.	0.2	0
381	Nuclear coexpression of NF-Î°B subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S224.	0.2	0
382	Nodal marginal zone mutational signature. Blood, 2016, 128, 1315-1316.	0.6	0
383	Re-Defining â€˜Reactiveâ€™ lymphadenopathies: How molecular lessons have changed our minds. Seminars in Diagnostic Pathology, 2018, 35, 1-3.	1.0	0
384	Updates from the central pathology review in patients with advanced stage mycosis fungoides (MF) and Sezary syndrome (SS) for the Global PROCLIPI study. European Journal of Cancer, 2018, 101, S16-S17.	1.3	0
385	Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma. Annals of Hematology, 2019, 98, 2837-2839.	0.8	0
386	Large cells with CD30 expression and Hodgkin-like features in primary cutaneous marginal zone B-cell lymphoma: a study of 13 cases. European Journal of Cancer, 2019, 119, S23.	1.3	0
387	An analysis of genetic targets for guiding clinical management of follicular lymphoma. Expert Review of Hematology, 2020, 13, 1361-1372.	1.0	0
388	Follicular Lymphoma: Design of a Protein-Based Survival Predictor Using Tissue-Microarrays (TMA).. Blood, 2004, 104, 2266-2266.	0.6	0
389	Mantle Cell Lymphoma Genotypes Identified with CGH to BAC Microarrays Define Clinical Subgroups of Disease and Strongly Predict Patient Outcome.. Blood, 2004, 104, 695-695.	0.6	0
390	Cytogenetic and FISH Study of 92 Patients with Splenic Marginal Zone B-Cell Lymphoma (SMZBCL).. Blood, 2004, 104, 699-699.	0.6	0
391	Clinical and Biological Relevance of NF-Î°B Activation in B-CLL.. Blood, 2004, 104, 2792-2792.	0.6	0
392	Identification of Surrogate Prognostic Markers and Genes Implicated in Immunoglobulin Gene (IgVH) Somatic Hypermutation in Small B-Cell Lymphomas.. Blood, 2005, 106, 1004-1004.	0.6	0
393	FOXP3 Expression in B and T Cell Lymphomas.. Blood, 2005, 106, 4503-4503.	0.6	0
394	Transcriptome Classification of B-Cell Non-Hodgkins Lymphoma.. Blood, 2006, 108, 819-819.	0.6	0
395	Splenic Marginal Zone Lymphoma Shows a Distinct Pattern of DNA Copy Number Aberrations That Correlates with Tumor Characteristics and Predicts Disease Outcome.. Blood, 2006, 108, 2422-2422.	0.6	0
396	The Expression of T Cell Receptor Signaling Genes Is Associated with Poor Response to IFN-Î± and/or PUVA in Mycosis Fungoides.. Blood, 2006, 108, 2053-2053.	0.6	0

#	Article	IF	Citations
397	The BCL6 Oncogene Drives an Epigenomic Program Linking Stem Cells to the Pathogenesis of Human Diffuse Large B Cell Lymphoma in Mice.. Blood, 2007, 110, 3372-3372.	0.6	0
398	Mycosis Fungoide: Immunochemistry Analysis of Lymphoid and Microenvironment Cells by Macrotissue Array.. Blood, 2007, 110, 4400-4400.	0.6	0
399	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. Blood, 2008, 112, 478-478.	0.6	0
400	Molecular Heterogeneity as a Basis for Rational Therapeutics in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 2348-2348.	0.6	0
401	A Novel Pro-Survival Function of Cyclin-D1 Underlies Its Oncogenic Role and Potential as a Therapeutic Target In Mantle Cell Lymphoma. Blood, 2010, 116, 769-769.	0.6	0
402	Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples. Blood, 2010, 116, 2470-2470.	0.6	0
403	PIM Kinases Inhibition, a Rational Strategy in Peripheral T-Cell Lymphomas,. Blood, 2011, 118, 3494-3494.	0.6	0
404	The NF-ÎºB-Inducing Kinase (NIK) Is Involved in Both Classical and Alternative NF-ÎºB Activation and Is Necessary for the Survival of T Cell Lymphoma Cells,. Blood, 2011, 118, 3665-3665.	0.6	0
405	Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen?. Blood, 2011, 118, 2638-2638.	0.6	0
406	PI3K Inhibition As a Potential Therapeutic Strategy in Peripheral T-Cell Lymphomas,. Blood, 2011, 118, 3493-3493.	0.6	0
407	Clonal Selection in the Ontogeny and Evolution of Splenic Marginal Zone Lymphoma Confirming the Existence of Distinct Molecular Subtypes. Blood, 2012, 120, 1556-1556.	0.6	0
408	Mutational Status of Splenic Marginal Zone Lymphoma Revealed by Whole Exome Sequencing.. Blood, 2012, 120, 2698-2698.	0.6	0
409	Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas. Blood, 2012, 120, 300-300.	0.6	0
410	Abstract 3533: Clinical impact of NF-KB activation in diffuse large B cell lymphoma.. , 2013, , .		0
411	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 363-363.	0.6	0
412	Tumour Suppressor Genes in Hodgkinâ€™s Disease. , 1995, , 209-222.		0
413	Abstract 4202: Deciphering the effects of GNA13 mutations in B-cell lymphomas. , 2014, , .		0
414	NF-ÎºB Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2014, 124, 1620-1620.	0.6	0

#	Article	IF	Citations
415	Analysis of the Genomic Heterogeneity in Hodgkin Lymphoma Using Next Generation Sequencing. Blood, 2015, 126, 178-178.	0.6	0
416	Peripheral T-Cell Lymphomas in Spain: Profiling Clinical, Phenotypic and Genetic Characteristics in Spanish Population. Blood, 2018, 132, 2938-2938.	0.6	0
417	Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines. Blood, 2018, 132, 2851-2851.	0.6	0
418	Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia. Blood, 2018, 132, 5383-5383.	0.6	0
419	Splenic Marginal Zone Lymphoma. Encyclopedia of Pathology, 2020, , 474-479.	0.0	0
420	Search for the cause of anaemia and neutropenia in a patient with wellâ€controlled systemic lupus erythematosus. International Journal of Laboratory Hematology, 2022, 44, .	0.7	0
421	Abstract 4725: Efficacy of a new small-molecule inhibitor of histone deacetylase 6 (HDAC6) in preclinical models of B-cell lymphoma and acute myeloid leukemia. , 2019, , .		0